Neurocrine Biosciences Inc Market Cap ($13.03 Billion)
Market Cap & Net Worth: Neurocrine Biosciences Inc (NBIX)
Neurocrine Biosciences Inc market cap. Neurocrine Biosciences Inc (NASDAQ:NBIX) has a market capitalization of $13.03 Billion ($13.03 Billion) as of November 1, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #1763 globally and #685 in its home market, demonstrating a 1.96% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Neurocrine Biosciences Inc's stock price $146.10 by its total outstanding shares 100363463 (100.36 Million). Also see NBIX operating cash flow for how efficiently the company converts equity into cash flow.
Neurocrine Biosciences Inc Market Cap History (2015–2026)
Neurocrine Biosciences Inc market cap history from 2015 to 2026. Data shows growth from $5.68 Billion to $14.66 Billion (10.41% CAGR). Check NBIX stock price and chart for real-time trading data and today's change.
Index Memberships
Neurocrine Biosciences Inc is a constituent of 6 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
ARCA Biotechnology
BTK
|
$1.06 Trillion | 1.23% | #17 of 30 |
|
Dow Jones Biotechnology
DJUSBT
|
$1.15 Trillion | 1.14% | #11 of 39 |
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.50% | #31 of 976 |
|
NASDAQ Composite
IXIC
|
$40.09 Trillion | 0.03% | #208 of 3165 |
|
S&P Midcap 400
MID
|
$3.34 Trillion | 0.36% | #60 of 401 |
|
NASDAQ Biotechnology
NBI
|
$1.84 Trillion | 0.71% | #22 of 263 |
Weight: Neurocrine Biosciences Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Neurocrine Biosciences Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Neurocrine Biosciences Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore how fast is Neurocrine Biosciences Inc growing its equity to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
4.98x
Neurocrine Biosciences Inc's market cap is 4.98 times its annual revenue
Latest Price to Earnings (P/E) Ratio
29.74x
Neurocrine Biosciences Inc's market cap is 29.74 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $3.88 Billion | $15.00 Million | -$141.09 Million | 258.94x | N/A |
| 2017 | $7.79 Billion | $161.63 Million | -$142.54 Million | 48.18x | N/A |
| 2018 | $7.17 Billion | $451.24 Million | $21.11 Million | 15.88x | 339.49x |
| 2019 | $10.79 Billion | $788.10 Million | $37.00 Million | 13.69x | 291.57x |
| 2020 | $9.62 Billion | $1.05 Billion | $407.30 Million | 9.20x | 23.62x |
| 2021 | $8.55 Billion | $1.13 Billion | $89.60 Million | 7.54x | 95.40x |
| 2022 | $11.99 Billion | $1.49 Billion | $154.50 Million | 8.05x | 77.59x |
| 2023 | $13.22 Billion | $1.89 Billion | $249.70 Million | 7.01x | 52.96x |
| 2024 | $13.70 Billion | $2.36 Billion | $341.30 Million | 5.82x | 40.14x |
| 2025 | $14.23 Billion | $2.86 Billion | $478.60 Million | 4.98x | 29.74x |
Competitor Companies of NBIX by Market Capitalization
Companies near Neurocrine Biosciences Inc in the global market cap rankings as of November 1, 2026. Also see total assets of Neurocrine Biosciences Inc for a full breakdown of the balance sheet.
Key companies related to Neurocrine Biosciences Inc by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #511 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #535 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #593 globally with a market cap of $45.23 Billion USD ( CN¥309.13 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #619 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #511 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #535 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $46.62 |
| #593 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.23 Billion | CN¥48.46 |
| #619 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.30 |
Market Capitalization of Neurocrine Biosciences Inc (2015–2026)
Market capitalization of Neurocrine Biosciences Inc from 2015 to today. Between 2015 and today, Neurocrine Biosciences Inc's market cap moved from $5.68 Billion to $ 14.66 Billion, with a yearly change of 10.41%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $14.66 Billion | +3.01% |
| 2025 | $14.23 Billion | +3.90% |
| 2024 | $13.70 Billion | +3.60% |
| 2023 | $13.22 Billion | +10.31% |
| 2022 | $11.99 Billion | +40.24% |
| 2021 | $8.55 Billion | -11.14% |
| 2020 | $9.62 Billion | -10.83% |
| 2019 | $10.79 Billion | +50.53% |
| 2018 | $7.17 Billion | -7.96% |
| 2017 | $7.79 Billion | +100.49% |
| 2016 | $3.88 Billion | -31.59% |
| 2015 | $5.68 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Neurocrine Biosciences Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $13.03 Billion USD |
| MoneyControl | $13.03 Billion USD |
| MarketWatch | $13.03 Billion USD |
| marketcap.company | $13.03 Billion USD |
| Reuters | $13.03 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESS… Read more